IDXX - IDEXX Laboratories, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
218.49
+2.96 (+1.37%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close215.53
Open216.89
Bid218.49 x 1100
Ask218.53 x 1000
Day's Range214.25 - 219.08
52 Week Range176.11 - 256.22
Volume488,316
Avg. Volume496,080
Market Cap18.8B
Beta (3Y Monthly)1.51
PE Ratio (TTM)51.29
EPS (TTM)4.26
Earnings DateMay 1, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est247.25
Trade prices are not sourced from all markets
  • How Do Analysts See IDEXX Laboratories, Inc. (NASDAQ:IDXX) Performing In The Years Ahead?
    Simply Wall St.3 days ago

    How Do Analysts See IDEXX Laboratories, Inc. (NASDAQ:IDXX) Performing In The Years Ahead?

    The latest earnings announcement IDEXX Laboratories, Inc. (NASDAQ:IDXX) released in December 2018 suggested that the company gained from a robust tailwind...

  • Markit12 days ago

    See what the IHS Markit Score report has to say about Idexx Laboratories Inc.

    Idexx Laboratories Inc NASDAQ/NGS:IDXXView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is low for IDXX with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding IDXX are favorable with net inflows of $98.54 billion. This was the highest net inflow seen over the last one-year.Error parsing the SmartText Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • PR Newswire19 days ago

    IDEXX Laboratories to Release 2019 First Quarter Financial Results

    WESTBROOK, Maine, April 2, 2019 /PRNewswire/ -- IDEXX Laboratories, Inc. (IDXX), a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, has scheduled the release of its 2019 first quarter financial results for Wednesday, May 1, 2019 before the market opens. Individuals can access a live webcast of the conference call through a link on the IDEXX website, www.idexx.com/investors. To listen to the live conference call, please dial 1-800-230-1092 or 1-612-288-0337 and reference confirmation code 465882.

  • Hedge Funds Are Relatively Bullish About IDEXX Laboratories (IDXX), Look We Happened
    Insider Monkey21 days ago

    Hedge Funds Are Relatively Bullish About IDEXX Laboratories (IDXX), Look We Happened

    It is already common knowledge that individual investors do not usually have the necessary resources and abilities to properly research an investment opportunity. As a result, most investors pick their illusory “winners” by making a superficial analysis and research that leads to poor performance on aggregate. Since stock returns aren't usually symmetrically distributed and index […]

  • Here's Why You Should Buy IDEXX Laboratories (IDXX) Stock
    Zacks24 days ago

    Here's Why You Should Buy IDEXX Laboratories (IDXX) Stock

    The innovation-based, multi-modality global strategy, enabled by enhanced commercial capability, accelerates IDEXX's (IDXX) recurring CAG Diagnostics revenue growth.

  • Neogen (NEOG) Earnings and Revenues Miss Estimates in Q3
    Zacks25 days ago

    Neogen (NEOG) Earnings and Revenues Miss Estimates in Q3

    Continued weakness in the global animal protein market and strongly negative currency conversions posed as headwinds for Neogen (NEOG) in third-quarter fiscal 2019.

  • If You Had Bought IDEXX Laboratories (NASDAQ:IDXX) Shares Five Years Ago You'd Have Made 261%
    Simply Wall St.26 days ago

    If You Had Bought IDEXX Laboratories (NASDAQ:IDXX) Shares Five Years Ago You'd Have Made 261%

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on a lighter note, a goo...

  • Here's Why You Should Retain Patterson Companies (PDCO) Stock
    Zackslast month

    Here's Why You Should Retain Patterson Companies (PDCO) Stock

    A diversified product portfolio and strong Dental business prospects provide Patterson Companies (PDCO) a competitive edge in the MedTech space.

  • Here's Why You Should Invest in Integer Holdings (ITGR) Stock
    Zackslast month

    Here's Why You Should Invest in Integer Holdings (ITGR) Stock

    Integer Holdings (ITGR) is likely to gain from the Cardio & Vascular, Neuromodulation and Non-Medical Electrochem markets.

  • HealthEquity (HQY) Earnings & Revenues Beat Estimates in Q4
    Zackslast month

    HealthEquity (HQY) Earnings & Revenues Beat Estimates in Q4

    HealthEquity (HQY) witnesses strong HSA member growth in the fourth quarter of fiscal 2019.

  • Allscripts Partners With Opargo to Boost Practice Management
    Zackslast month

    Allscripts Partners With Opargo to Boost Practice Management

    Allscripts' (MDRX) partnership with Opargo is likely to improve scheduling capabilities and practice workflows of Allscripts Practice Management solution.

  • Stryker Buys Israel-Based OrthoSpace, Strengthens MedSurg
    Zackslast month

    Stryker Buys Israel-Based OrthoSpace, Strengthens MedSurg

    Strong international presence and an acquisition-driven strategy are likely to fortify Stryker's (SYK) footprint in the global MedTech space.

  • Allscripts Strengthens Strategic Relationship with Pulse8
    Zackslast month

    Allscripts Strengthens Strategic Relationship with Pulse8

    Pulse8 is likely to boost Allscripts' (MDRX) flagship platform Veradigm, and its existing health plan product suite that delivers pocket-friendly tools and services for health plan members.

  • Here's Why Investors Should Retain McKesson (MCK) Stock Now
    Zackslast month

    Here's Why Investors Should Retain McKesson (MCK) Stock Now

    McKesson (MCK) is well positioned for growth backed by strong business plans and robust surprise trend amid cutthroat competition in the near term.

  • Allscripts to Fortify Middle East Foothold With New Project
    Zackslast month

    Allscripts to Fortify Middle East Foothold With New Project

    Qatar-based Alfardan Group and Chicago-based Northwestern Medicine select Allscripts (MDRX) for the launch of a project in the Middle East.

  • Here's Why Investors Should Bet on Cooper Companies (COO) Now
    Zackslast month

    Here's Why Investors Should Bet on Cooper Companies (COO) Now

    Cooper Companies (COO) maintains its leading position in the markets of specialty lenses. Further, the company exits first-quarter fiscal 2019 on a strong note.

  • Here's Why Investors Should Bet on Merit Medical (MMSI) Now
    Zackslast month

    Here's Why Investors Should Bet on Merit Medical (MMSI) Now

    Merit Medical's (MMSI) upbeat guidance for 2019 is indicative of the company's brighter prospects.

  • Baxter (BAX) Gets FDA Approval for Eptifibatide to Treat ACS
    Zackslast month

    Baxter (BAX) Gets FDA Approval for Eptifibatide to Treat ACS

    Baxter's (BAX) Eptifibatide is a platelet aggregation inhibitor that prevents platelets-specialized blood cells clotting.

  • Here's Why You Should Invest in AngioDynamics Stock Now
    Zacks2 months ago

    Here's Why You Should Invest in AngioDynamics Stock Now

    Expanding customer base of the NanoKnife platform is likely to fortify AngioDynamics' (ANGO) foothold in the Medical Instruments space.

  • PR Newswire2 months ago

    IDEXX Names Sharon Underberg General Counsel

    WESTBROOK, Maine , March 4, 2019 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, today announced ...

  • Why IDEXX Laboratories, Inc. (NASDAQ:IDXX) Could Be Worth Watching
    Simply Wall St.2 months ago

    Why IDEXX Laboratories, Inc. (NASDAQ:IDXX) Could Be Worth Watching

    Today we're going to take a look at the well-established IDEXX Laboratories, Inc. (NASDAQ:IDXX). The company's stock saw a decent share price growth in the teens level on the NASDAQGSRead More...

  • GuruFocus.com2 months ago

    IDEXX Laboratories Inc (IDXX) Files 10-K for the Fiscal Year Ended on December 31, 2018

    IDEXX Laboratories Inc develops, manufactures and distributes products and provide services for companion animal veterinary, livestock and poultry, dairy and water testing markets. IDEXX Laboratories Inc had annual average EBITDA growth of 13.10% over the past ten years. GuruFocus rated IDEXX Laboratories Inc the business predictability rank of 5-star.